Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum h6 + lactobacillus fermentum cqpc04
- Development stage
- Preclinical
- Lead developer
- Chongqing University of Education
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum H6 + Lactobacillus fermentum CQPC04 is a probiotic combination consisting of two specific lactic acid bacteria strains. This combination has been primarily investigated for its potential therapeutic effects on metabolic disorders, including obesity, hyperlipidemia, and non-alcoholic fatty liver disease (NAFLD). Research conducted by institutions such as Chongqing University of Education suggests that these strains work synergistically to modulate the gut microbiota, reduce systemic inflammation, and regulate lipid metabolism. The mechanism of action involves the activation of the AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPAR-alpha) pathways, which helps to inhibit fat accumulation and improve lipid profiles. Most studies to date have been conducted in animal models, demonstrating significant reductions in body weight, liver fat, and serum cholesterol levels.
- Other names
- L. plantarum H6 + L. fermentum CQPC04Lactobacillus plantarum H6 + Lactobacillus fermentum CQPC04
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on lactobacillus plantarum h6 + lactobacillus fermentum cqpc04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum h6 + lactobacillus fermentum cqpc04.